



Neuren (NEU) – ASX Announcement

12 May 2026

Launch of Investor Hub and new website to enhance shareholder engagement

Melbourne, Australia: Neuren Pharmaceuticals (ASX: NEU) has launched an Investor Hub and new company website (www.neurenpharma.com) designed to enhance engagement and communication with shareholders, prospective investors and any other stakeholders interested in learning more about Neuren and its business.

Neuren CEO Jon Pilcher commented: "As we continue to advance innovative therapies for neurological conditions and execute our strategy for 2026 and beyond, the new Investor Hub and website reflect our ongoing commitment to improving communication and accessibility for all stakeholders."

Shareholders and other stakeholders can access and register for the Investor Hub [here](#) or by scanning the QR code below and following the prompts.

Existing subscribers to e-mail alerts on Neuren's previous website have been transferred to the new website. However, we encourage existing subscribers to join the Investor Hub to access enhanced and more interactive features.

Click [here](#) to view this announcement on our Investor Hub.

About Neuren

Neuren Pharmaceuticals is developing new drug therapies to treat multiple serious neurological disorders caused by genetic abnormalities or brain injury, that have no or limited approved treatment options. Neuren's therapies target the critical role of Insulin-like growth factor 1 (IGF-1) in the brain, using orally administered analogs of naturally occurring peptides.

DAYBUE® (trofinetide) oral solution is approved by the US Food and Drug Administration (FDA), Health Canada and the Ministry of Health in Israel and DAYBUE STIX (trofinetide) powder is approved by the FDA for the treatment of Rett syndrome. Neuren has granted an exclusive worldwide license to Acadia Pharmaceuticals Inc. for the development and commercialization of trofinetide.

Neuren's second drug candidate, NNZ-2591, is in clinical development as an oral solution treatment for multiple neurodevelopmental disorders, with positive results achieved in Phase 2 clinical trials in Phelan-McDermid syndrome, Pitt Hopkins syndrome and Angelman syndrome. Each of these programs has been granted "orphan drug" designation in the United States and the European Union as well as Fast Track and Rare Pediatric Disease designations from the FDA. Neuren is also developing NNZ-2591 for the treatment of hypoxic ischemic encephalopathy (HIE), a serious condition caused by brain injury before or shortly after birth.

Currently, Neuren is conducting a Phase 3, randomized, double-blind, placebo-controlled clinical trial ("Koala") evaluating the safety and efficacy of NNZ-2591 in children aged 3 to 12 years with Phelan-McDermid syndrome and a 52-week open-label extension study.



Contact:

investorrelations@neurenpharma.com

ASX Listing Rules information

This announcement was authorized to be given to the ASX by CEO of Neuren Pharmaceuticals Limited, Suite 1.01, 117 Camberwell Road, Hawthorn East, VIC 3123

Investor Hub



Forward-looking Statements

This announcement contains forward-looking statements that are subject to risks and uncertainties. Such statements involve known and unknown risks and important factors that may cause the actual results, performance or achievements of Neuren to be materially different from the statements in this announcement.